• Je něco špatně v tomto záznamu ?

COVID-19 influenced gut dysbiosis, post-acute sequelae, immune regulation, and therapeutic regimens

ST. Raj, AW. Bruce, M. Anbalagan, H. Srinivasan, S. Chinnappan, M. Rajagopal, K. Khanna, HC. Chandramoorthy, RR. Mani

. 2024 ; 14 (-) : 1384939. [pub] 20240528

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013846

The novel coronavirus disease 2019 (COVID-19) pandemic outbreak caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has garnered unprecedented global attention. It caused over 2.47 million deaths through various syndromes such as acute respiratory distress, hypercoagulability, and multiple organ failure. The viral invasion proceeds through the ACE2 receptor, expressed in multiple cell types, and in some patients caused serious damage to tissues, organs, immune cells, and the microbes that colonize the gastrointestinal tract (GIT). Some patients who survived the SARS-CoV-2 infection have developed months of persistent long-COVID-19 symptoms or post-acute sequelae of COVID-19 (PASC). Diagnosis of these patients has revealed multiple biological effects, none of which are mutually exclusive. However, the severity of COVID-19 also depends on numerous comorbidities such as obesity, age, diabetes, and hypertension and care must be taken with respect to other multiple morbidities, such as host immunity. Gut microbiota in relation to SARS-CoV-2 immunopathology is considered to evolve COVID-19 progression via mechanisms of biochemical metabolism, exacerbation of inflammation, intestinal mucosal secretion, cytokine storm, and immunity regulation. Therefore, modulation of gut microbiome equilibrium through food supplements and probiotics remains a hot topic of current research and debate. In this review, we discuss the biological complications of the physio-pathological effects of COVID-19 infection, GIT immune response, and therapeutic pharmacological strategies. We also summarize the therapeutic targets of probiotics, their limitations, and the efficacy of preclinical and clinical drugs to effectively inhibit the spread of SARS-CoV-2.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013846
003      
CZ-PrNML
005      
20240905134223.0
007      
ta
008      
240725e20240528sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fcimb.2024.1384939 $2 doi
035    __
$a (PubMed)38863829
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Raj, Sterlin T $u Department of Molecular Biology, Ekka Diagnostics, Chennai, Tamil Nadu, India
245    10
$a COVID-19 influenced gut dysbiosis, post-acute sequelae, immune regulation, and therapeutic regimens / $c ST. Raj, AW. Bruce, M. Anbalagan, H. Srinivasan, S. Chinnappan, M. Rajagopal, K. Khanna, HC. Chandramoorthy, RR. Mani
520    9_
$a The novel coronavirus disease 2019 (COVID-19) pandemic outbreak caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has garnered unprecedented global attention. It caused over 2.47 million deaths through various syndromes such as acute respiratory distress, hypercoagulability, and multiple organ failure. The viral invasion proceeds through the ACE2 receptor, expressed in multiple cell types, and in some patients caused serious damage to tissues, organs, immune cells, and the microbes that colonize the gastrointestinal tract (GIT). Some patients who survived the SARS-CoV-2 infection have developed months of persistent long-COVID-19 symptoms or post-acute sequelae of COVID-19 (PASC). Diagnosis of these patients has revealed multiple biological effects, none of which are mutually exclusive. However, the severity of COVID-19 also depends on numerous comorbidities such as obesity, age, diabetes, and hypertension and care must be taken with respect to other multiple morbidities, such as host immunity. Gut microbiota in relation to SARS-CoV-2 immunopathology is considered to evolve COVID-19 progression via mechanisms of biochemical metabolism, exacerbation of inflammation, intestinal mucosal secretion, cytokine storm, and immunity regulation. Therefore, modulation of gut microbiome equilibrium through food supplements and probiotics remains a hot topic of current research and debate. In this review, we discuss the biological complications of the physio-pathological effects of COVID-19 infection, GIT immune response, and therapeutic pharmacological strategies. We also summarize the therapeutic targets of probiotics, their limitations, and the efficacy of preclinical and clinical drugs to effectively inhibit the spread of SARS-CoV-2.
650    12
$a COVID-19 $x imunologie $x komplikace $x terapie $7 D000086382
650    _2
$a lidé $7 D006801
650    12
$a dysbióza $7 D064806
650    12
$a střevní mikroflóra $7 D000069196
650    12
$a SARS-CoV-2 $x imunologie $7 D000086402
650    _2
$a postakutní syndrom COVID-19 $7 D000094024
650    _2
$a probiotika $x terapeutické užití $7 D019936
650    _2
$a gastrointestinální trakt $x mikrobiologie $7 D041981
650    _2
$a farmakoterapie COVID-19 $7 D000093485
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Bruce, Alexander W $u Faculty of Science, University of South Bohemia, České Budějovice, Czechia
700    1_
$a Anbalagan, Muralidharan $u Department of Structural & Cellular Biology, Tulane University School of Medicine, New Orleans, LA, United States
700    1_
$a Srinivasan, Hemalatha $u School of Life Sciences, B. S. Abdur Rahman Crescent Institute of Science and Technology, Chennai, India
700    1_
$a Chinnappan, Sasikala $u Department of Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, University College of Sedaya International UCSI University, Kuala Lumpur, Malaysia
700    1_
$a Rajagopal, Mogana $u Department of Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, University College of Sedaya International UCSI University, Kuala Lumpur, Malaysia
700    1_
$a Khanna, Kushagra $u Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur, Malaysia
700    1_
$a Chandramoorthy, Harish C $u Department of Microbiology and Clinical Parasitology, College of Medicine, King Khalid University, Abha, Saudi Arabia $u Center for Stem Cell Research, College of Medicine, King Khalid University, Abha, Saudi Arabia
700    1_
$a Mani, Ravishankar Ram $u Department of Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, University College of Sedaya International UCSI University, Kuala Lumpur, Malaysia
773    0_
$w MED00182987 $t Frontiers in cellular and infection microbiology $x 2235-2988 $g Roč. 14 (20240528), s. 1384939
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38863829 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134217 $b ABA008
999    __
$a ok $b bmc $g 2143575 $s 1225712
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 14 $c - $d 1384939 $e 20240528 $i 2235-2988 $m Frontiers in cellular and infection microbiology $n Front Cell Infect Microbiol $x MED00182987
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace